Sort
48,018 grants matching “immunotherapy”
Immunoengineering Strategies for Musculoskeletal Trauma
$482,585Robert E Guldberg · University Of Oregon · R01 · FY2021 · AR
The function of PLZF in innate T cells
$482,565Derek B. Sant'angelo · Rbhs-Robert Wood Johnson Medical School · R01 · FY2014 · AI
Breast Cancer Treatment with Antibody Targeted T Cells
$482,535Lawrence G Lum · Roger Williams Hospital · R01 · FY2006 · CA
Cell and Gene Therapy, Clinical Manufacture and Monitoring Core
$482,531Antoni Ribas · California Institute Of Technology · P01 · FY2010 · CA
The role of TIM-3 in regulating T cell function during tuberculosis
$482,447Samuel M Behar · Brigham And Women'S Hospital · P01 · FY2015 · AI
Regulation by Gammadelta T Cells of Autoimmune Uveitis (EAU)
$482,399Deming Sun · Doheny Eye Institute · R01 · FY2012 · EY
Molecular Mechanisms Underlying Dendritic Cell Adaptations During Chronic Infection
$482,297Elina I Zuniga · University Of California, San Diego · R01 · FY2022 · AI
Molecular Mechanisms Underlying Dendritic Cell Adaptations During Chronic Infection
$482,297Elina I Zuniga · University Of California, San Diego · R01 · FY2024 · AI
Molecular Mechanisms Underlying Dendritic Cell Adaptations During Chronic Infection
$482,297Elina I Zuniga · University Of California, San Diego · R01 · FY2023 · AI
UCLA Tumor Immunology Training Program
$482,270Michael A Teitell · University Of California Los Angeles · T32 · FY2016 · CA
AHR-mediated immunosuppression in glioblastoma
$482,198Francisco J. Quintana · Brigham And Women'S Hospital · R01 · FY2020 · ES
Targeting PPT1 in the Tumor Microenvironment
$482,190Ravi K Amaravadi · Wistar Institute · P01 · FY2019 · CA
Cyclin Dependent Kinases as Epigenetic Therapy Targets
$482,163Jean-Pierre J Issa · Coriell Institute For Medical Research · P50 · FY2021 · CA
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach
$482,114Periasamy Selvaraj · Emory University · R01 · FY2017 · CA
Novel randomized controlled trials of vitamin D supplementation in patients with colorectal cancer: Impact on survival and biology
$482,064Kimmie Ng · Dana-Farber Cancer Inst · R01 · FY2019 · CA
Cytokines driving T cell dysregulation in lacrimal gland autoimmunity
$482,015Scott Matthew Lieberman · University Of Iowa · R01 · FY2022 · EY
Cellular Transduction with Replication-Competent Retrovirus Vectors
$481,936Noriyuki Kasahara · University Of California Los Angeles · R01 · FY2009 · CA
Nanoscale delivery vehicles for antigen-based vaccines
$481,915Jean M Frechet · University Of California Berkeley · R01 · FY2008 · EB
Renalase inhibition for treatment of unresectable melanoma
$481,894Harriet M Kluger · Yale University · R01 · FY2020 · CA
Project 1: Innate immune responses triggered by Listeria monocytogenes
$481,868Daniel A Portnoy · University Of California Berkeley · P01 · FY2019 · AI
Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma
$481,846Hassane M Zarour · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA
Immunophysiological Mechanisms in the Biological Therapy of Cancer
$481,738Robert Wiltrout · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
Preclinical GEM and GDA Models of Primary and Metastatic Melanoma
$481,728Terry Van Dyke · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Targeting PPT1 in the Tumor Microenvironment
$481,705Ravi K Amaravadi · Wistar Institute · P01 · FY2023 · CA
Breaking down tumor immune privilege through targeted hypoxia reduction
$481,691Michael A. Curran · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA